72/100 B+ · Critical risk
1 serious risk flag found TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.
  • 🔴 Insolvency / collective proceedings on file (8)

CHRONOLIFE

Active Simplified joint-stock company (SAS) Scientific research & development Active for 10 years

Simplified joint-stock company (SAS) · RC 814816369 · Active since 2015

B+

Overview

CHRONOLIFE is a simplified joint-stock company (sas) registered in France, since 2015. The company operates in the scientific research & development sector. With reported revenue of 142K EUR in 2023. Its TraceComp score of 72 (B+) indicates moderate risk with some areas to watch.

Company Information

Registration Number
814816369
Legal Form
Simplified joint-stock company (SAS)
Registered
2015-11-18

Financial Profile

Latest filed accounts: FY 2023 · most recent available in public filings

Revenue (2023) 141,894 EUR
Net Income -3,060,100 EUR
Total Assets 810,879 EUR
Altman Z -27.08 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

7 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
BRUNO Cervera Officer Current
+ 6 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Insolvency & Collective Proceedings

8 insolvency / collective-proceedings notices on file — most recent published 2026-05-17. A material adverse finding for counterparty and credit risk.

Insolvency notice types, titles, publication dates and official Gazette sources.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 3 patents · 3 active · 3 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Net loss reported in FY 2023
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.